MedPath

A randomized phase III study comparing induction chemotherapy to daily low dose Cisplatin both combined with high dose radiotherapy in patients with inoperable non-small cell lung cancer stage I, II and III.

Completed
Registration Number
NL-OMON22854
Lead Sponsor
/A
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

1. Pathologically confirmed Non-small cell lung cancer;

2. Medically inoperable or irresectable NSCLC T 1-4, N0-3, M0;

Exclusion Criteria

1. Previous chemotherapy and/or radiotherapy of the chest;

2. Superior Vena cava syndrome;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Disease-free survival, local control, pattern of recurrence.
Secondary Outcome Measures
NameTimeMethod
Acute and late toxicity, Quality of Life.
© Copyright 2025. All Rights Reserved by MedPath